Search Results

Your search for Syed Ali Abutalib, MD, and Miguel-Angel Perales, MD matches 2 pages

Showing 1 - 2

By Syed Ali Abutalib, MD, and Miguel-Angel Perales, MD / March 10, 2022 / 2021 ASH Annual Meeting & Exposition

CAR T-Cell Therapy as Second-Line Treatment in Large B-Cell Lymphomas

“The mind is not a vessel to be filled but a fire to be kindled.” —Plutarch About 30% to 40% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) experience relapse, and 10% are refractory to the...

hematologic malignancies

By Alice Goodman / March 25, 2020

HAPLO2019: Advances in Haploidentical Transplantation and Other Novel Cellular Therapies

Now in its seventh year, the Haploidentical Transplant Symposium (HAPLO) continues to explore advances in haploidentical and other novel cellular therapies. The most recent of these meetings—HAPLO2019—met in Orlando, Florida, 2 days before the start of the 2019 American Society of Hematology (ASH)...

Dec

Today In Oncology

Search Results

Your search for Syed Ali Abutalib, MD, and Miguel-Angel Perales, MD matches 2 pages

CAR T-Cell Therapy as Second-Line Treatment in Large B-Cell Lymphomas

HAPLO2019: Advances in Haploidentical Transplantation and Other Novel Cellular Therapies

Combination of Two Oral Agents May Improve Progression Free Survival in Patients With Previously Untreated CLL

Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma

Primary Analysis of ZUMA-2 Treatment of BTK Inhibitor-Naive Relapsed Refractory Mantle Cell Lymphoma

FDA Grants Accelerated Approval to Encorafenib Combination for BRAF V600E–Mutant Metastatic Colorectal Cancer

SEQUOIA 5-Year Follow-up Zanubrutinib vs Bendamustine/Rituximab in Treatment-Naive CLL/SLL